Pharmaceutical

Walden Biosciences teams up with Primula for kidney disease study 

Walden reported positive topline data from a Phase I clinical trial of its lead candidate WAL0921, a humanised mAb to treat kidney disease.

May 15, 2024 - 04:00
Walden Biosciences teams up with Primula for kidney disease study 
Walden reported positive topline data from a Phase I clinical trial of its lead candidate WAL0921, a humanised mAb to treat kidney disease.
Read the original article

Tags:

Previous Article

Bayer reports drop in Q1 sales amidst patent litigation challenges

Next Article

AbbVie makes psychedelic play with $2bn Gilgamesh collaboration

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sirolimus by OrphAI Therapeutics for Bronchiolitis Obli...

Dec 6, 2023

Opinion: The end of affirmative action means it’s time to revise pre-med requirements

Opinion: The end of affirmative action means it’s time ...

Nov 11, 2023

STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale

STAT+: After sickle-cell screwups, Bluebird Bio’s only ...

Dec 11, 2023